A new therapeutic effect of fenofibrate in Duchenne muscular dystrophy: The promotion of myostatin degradation.

Zeren SunDengqiu XuLei ZhaoXihua LiSijia LiXiaofei HuangChunjie LiLixin SunBing LiuZhenzhou JiangLuyong Zhang

Published in: British journal of pharmacology (2021)

Fenofibrate substantially slows muscle dystrophy by promoting the degradation of myostatin protein, which may indicate a new therapeutic focus for DMD patients.

Keyphrases

duchenne muscular dystrophy
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
skeletal muscle
muscular dystrophy
early onset
protein protein